China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

Illumina is an applied genomics technology ... The advancements have made it possible to image on dual-surfaces and process multiple flow cells, and huge increases in densities have meant multiple ...

the complexity of the process has made it challenging to integrate or manage efficiently and at scale. To be successful, health care organizations ... Illumina recently launched the MiSeq i100 and ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

I am confident in Illumina's opportunities and our long-term success.” Casualties of the acquisition process had already emerged prior to this, as the company’s CEO of 10-years, Francis ...

Illumina (ILMN) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...